This is a Phase Ib/II, open-label, umbrella study evaluating the efficacy and safety of
multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping
of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.